Mannatech Announces Late Filing of Annual Report

Nutritional supplement company cites automatic extension to file 2025 Form 10-K by April 15th.

Apr. 1, 2026 at 11:26pm

Mannatech, Incorporated, a global health and wellness company, announced that it has filed a Form 12b-25 with the SEC, notifying of a late filing of its annual report on Form 10-K for the fiscal year ended December 31, 2025. The company expects to file the 2025 Form 10-K as soon as practicable by April 15, 2026, in accordance with the automatic 15-day extension provided by the 12b-25 filing.

Why it matters

Timely filing of financial reports is a key requirement for publicly traded companies. Mannatech's late filing could raise concerns among investors and regulators about the company's financial health and internal controls, potentially impacting the stock price and the company's reputation.

The details

Mannatech cited the impact of COVID-19 on its business as one of the reasons for the late filing. The company has until April 15, 2026, to submit the 2025 Form 10-K, which is the annual report that provides a comprehensive overview of the company's financial performance and operations for the previous fiscal year.

  • Mannatech's 2025 Form 10-K was due on March 31, 2026.
  • Mannatech filed a Form 12b-25 to obtain an automatic 15-day extension to file the 2025 Form 10-K.
  • Mannatech expects to file the 2025 Form 10-K as soon as practicable by April 15, 2026.

The players

Mannatech, Incorporated

A leading global health and wellness company that develops and sells nutritional supplements and other wellness products.

Got photos? Submit your photos here. ›

What’s next

Investors and regulators will be closely monitoring Mannatech's progress in filing the 2025 Form 10-K by the April 15th deadline. Any further delays or issues could lead to increased scrutiny and potential consequences for the company.

The takeaway

Mannatech's late filing of its annual report highlights the importance of maintaining robust financial reporting processes, especially for publicly traded companies. The delay could undermine investor confidence and raise concerns about the company's overall financial health and management.